Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia

被引：6

作者：

Ding, Hilda ^{[1
]}

Hashem, Hasan ^{[1
]}

Cabral, Linda ^{[1
]}

Rangarajan, Hemalatha ^{[2
]}

Abusin, Ghada ^{[3
]}

Lazarus, Hillard M. ^{[4
]}

Abu-Arja, Rolla ^{[2
]}

机构：

[1] Case Med Ctr, Pediat Hematol Oncol & Bone Marrow Transplantat, Univ Hosp Rainbow Babies & Childrens Hosp, Cleveland, OH USA

[2] Nationwide Childrens Hosp, Pediat Hematol Oncol & Bone Marrow Transplant, Columbus, OH USA

[3] Univ Iowa, Childrens Hosp, Pediat Hematol Oncol & Bone Marrow Transplant, Iowa City, IA USA

[4] Univ Hosp Case Med Ctr, Dept Haematol & Med Oncol, Cleveland, OH USA

来源：

PEDIATRIC TRANSPLANTATION | 2017年 / 21卷 / 02期

关键词：

acute myeloid leukemia; azacitidine; donor lymphocyte infusion; Fanconi anemia; hematopoietic cell transplant; pediatric; CONVENTIONAL CARE REGIMENS; SALVAGE THERAPY; CHILDREN; AML; CHEMOTHERAPY; DECITABINE; RELAPSE; MDS;

D O I：

10.1111/petr.12870

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

HCT is the definitive therapy for patients with FA and AML. Conventional cytotoxic agents cause potential DNA damage, and currently, there is no established regimen for these patients prior to HCT. A 13-year-old male with FA and refractory AML was given azacitidine, achieved morphologic remission and underwent HCT. At 95 days after HCT, he relapsed. Azacitidine along with DLI was used as first salvage therapy. Azacitidine was overall well tolerated with minimal side effects. In patients with AML and FA, azacitidine can be considered an alternative to conventional chemotherapy.

引用

页数：3

共 50 条

[1] Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia
Talbot, Alexis
de Latour, Regis Peffault
Raffoux, Emmanuel
Buchbinder, Nimrod
Vigouroux, Stephane
Milpied, Noel
Leblanc, Thierry
Soulier, Jean
Michallet, Mauricette
Socie, Gerard
HAEMATOLOGICA, 2014, 99 (10) : E199 - E200
[2] Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia
Tamura, Akihiro
Ishida, Toshiaki
Saito, Atsuro
Yamamoto, Nobuyuki
Yokoi, Takehito
Uemura, Suguru
Nino, Nanako
Fujiwara, Takahiro
Tahara, Teppei
Nakamura, Sayaka
Kozaki, Aiko
Kishimoto, Kenji
Hasegawa, Daiichiro
Kosaka, Yoshiyuki
PEDIATRIC BLOOD & CANCER, 2018, 65 (10)
[3] Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies
Maples, Kathryn T.
Sabo, Roy T.
McCarty, John M.
Toor, Amir A.
Hawks, Kelly G.
LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 2836 - 2841
[4] Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia
Appelbaum, Frederick R.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2017, 30 (04) : 320 - 326
[5] Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis
Li, Xuefeng
Wang, Wen
Zhang, Xin
Wu, Yu
FRONTIERS IN ONCOLOGY, 2022, 12
[6] Allogeneic hematopoietic cell transplantation in acute myeloid leukemia
Magee, Gray
Ragon, Brittany Knick
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2023, 36 (02)
[7] Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
Rautenberg, Christina
Bergmann, Anika
Germing, Ulrich
Fischermanns, Caroline
Pechtel, Sabrina
Kaivers, Jennifer
Jager, Paul
Schuler, Esther
Haas, Rainer
Kobbe, Guido
Schroeder, Thomas
CANCERS, 2020, 12 (08) : 1 - 15
[8] Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia
Chen, Tzu-Ting
Lin, Ching-Chan
Lo, Wen-Jyi
Hsieh, Ching-Yun
Lein, Ming-Yu
Lin, Che-Hung
Lin, Chen-Yuan
Bai, Li-Yuan
Chiu, Chang-Fang
Yeh, Su-Peng
CANCERS, 2024, 16 (06)
[9] Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation
Yoshimoto, Goichi
Mori, Yasuo
Kato, Koji
Odawara, Jun
Kuriyama, Takuro
Ueno, Toshiyuki
Obara, Teppei
Yurino, Ayano
Yoshida, Shuro
Ogawa, Ryosuke
Ohno, Yuju
Iwasaki, Hiromi
Eto, Tetsuya
Akashi, Koichi
Miyamoto, Toshihiro
LEUKEMIA & LYMPHOMA, 2021, 62 (12) : 2939 - 2948
[10] Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia
Huschart, Emily
Miller, Holly
Salzberg, Dana
Campbell, Courtney
Beebe, Kristen
Schwalbach, Charlotte
Magee, Kyrie
Adams, Roberta H.
Ngwube, Alexander
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2021, 38 (02) : 154 - 160

← 1 2 3 4 5 →